Loading…
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $25M | $-154M | $-144M | $-130M | -47.0% | -87.9% | -319.0% |
| 2024 | $211M | $51M | $66M | $-45M | 15.3% | 63.4% | - |
| 2023 | $129M | $-0M | $-7M | $134M | -2.8% | - | - |
| 2022 | $0M | $-95M | $-95M | $-97M | -44.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 129.01 | 210.78 | 25.42 |
| Operating Expense | 97.25 | 132.18 | 163.77 | 183.32 |
| Operating Income | -97.25 | -3.16 | 47.01 | -157.90 |
| EBITDA | -95.35 | -0.32 | 50.78 | -153.80 |
| EBIT | -97.25 | -3.16 | 47.01 | -157.90 |
| Pretax Income | -94.62 | 12.06 | 66.48 | -142.83 |
| Tax Provision | 0 | 18.74 | 0.86 | 0.92 |
| Net Income | -94.62 | -6.68 | 65.63 | -143.75 |
| Net Income Common Stockholders | -94.62 | -6.68 | 65.63 | -143.75 |
| Total Expenses | 97.25 | 132.18 | 163.77 | 183.32 |
| Interest Income | 2.63 | 15.22 | 19.47 | 15.07 |
| Research And Development | 66.61 | 99.88 | 125.31 | 142.27 |
| Selling General And Administration | 30.64 | 32.29 | 38.47 | 41.05 |
| Normalized EBITDA | -95.35 | -0.32 | 50.78 | -153.80 |
| Normalized Income | -94.62 | -6.68 | 65.63 | -143.75 |
| Basic EPS | -3.02 | -0.20 | 1.76 | -3.47 |
| Diluted EPS | -3.02 | -0.20 | 1.68 | -3.47 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0.21 | 0.01 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -94.62 | -6.68 | 65.63 | -143.75 |
| Reconciled Depreciation | 1.90 | 2.84 | 3.77 | 4.10 |
| Net Interest Income | 2.63 | 15.22 | 19.47 | 15.07 |
| Net Income From Continuing And Discontinued Operation | -94.62 | -6.68 | 65.63 | -143.75 |
| Total Operating Income As Reported | -97.25 | -3.16 | 47.01 | -157.90 |
| Diluted Average Shares | 31.29 | 33.05 | 39 | 41.37 |
| Basic Average Shares | 31.29 | 33.05 | 37.31 | 41.37 |
| Diluted NI Availto Com Stockholders | -94.62 | -6.68 | 65.63 | -143.75 |
| Net Income Including Noncontrolling Interests | -94.62 | -6.68 | 65.63 | -143.75 |
| Net Income Continuous Operations | -94.62 | -6.68 | 65.63 | -143.75 |
| Net Non Operating Interest Income Expense | 2.63 | 15.22 | 19.47 | 15.07 |
| Total Other Finance Cost | -2.63 | 0 | 0 | 0 |
| Interest Income Non Operating | 2.63 | 15.22 | 19.47 | 15.07 |
| General And Administrative Expense | 30.64 | 32.29 | 38.47 | 41.05 |
| Other Gand A | 30.64 | 32.29 | 38.47 | 41.05 |
| Operating Revenue | 0 | 129.01 | 210.78 | 25.42 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Entrada Therapeutics, Inc.this co. | TRDA | $494M | - | 1.50 | -47.0% | -1.40 |
| Tactile Systems Technology, Inc. | TCMD | $512M | 27.44 | 2.31 | 8.7% | 12.18 |
| Altimmune, Inc. | ALT | $511M | - | 1.30 | -39.2% | -1.10 |
| Tectonic Therapeutic, Inc. | TECX | $510M | - | 2.02 | -29.5% | -3.09 |
| Aquestive Therapeutics, Inc. | AQST | $503M |
| - |
| -14.67 |
| 248.9% |
| -5.90 |
| XOMA Royalty Corporation | XOMA | $497M | 28.08 | 5.79 | 37.8% | 38.75 |
| Esperion Therapeutics, Inc. | ESPR | $492M | - | -1.55 | 7.5% | 14.42 |
| ADC Therapeutics SA | ADCT | $481M | - | -2.56 | 76.7% | -6.25 |
| Fulcrum Therapeutics, Inc. | FULC | $476M | - | 1.36 | -21.5% | -1.75 |
| Peer Median | - | 27.76 | 1.33 | 8.1% | -1.43 | |